Baijin Life Science Holdings Limited (HKG:1466)

Hong Kong · Delayed Price · Currency is HKD

1.740

-0.160 (-8.42%)

Oct 2, 2026, 4:08 PM HKT

Market Cap	1.62B +275.0%
Revenue (ttm)	89.30M -34.1%
Net Income	-37.87M
EPS	-0.06
Shares Out	932.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,403,000
Open	1.845
Previous Close	1.900
Day's Range	1.715 - 1.845
52-Week Range	0.465 - 1.960
Beta	-0.60
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About HKG:1466

Baijin Life Science Holdings Limited, together with its subsidiaries, engages in the procurement, processing, design, production, and wholesale distribution of pearls and fine jewelry products in Hong Kong, the People’s Republic of China, the United States, and internationally. It operates through three segments: Jewellery Business, Skincare Business, and Strategic Investment. The company is involved in the research and development of cellular and large molecule drugs; clinical research services; research, development, and sale of medical devic... [Read more]

Industry Luxury Goods

Sector Consumer Discretionary

Founded 2014

Employees 84

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 1466

Full Company Profile

Financial Performance

In fiscal year 2026, HKG:1466's revenue was 89.30 million, a decrease of -34.12% compared to the previous year's 135.56 million. Losses were -37.87 million, 11883.2% more than in 2025.

Financial Statements